LifeMD, Inc. Files Definitive Proxy Statement (DEF 14A)
Ticker: LFMDP · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 948320
Sentiment: neutral
Topics: LifeMD, DEF 14A, Proxy Statement, Corporate Governance, Shareholder Meeting
TL;DR
<b>LifeMD, Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023.</b>
AI Summary
LifeMD, Inc. (LFMDP) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. LifeMD, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 29, 2024. The filing covers the fiscal year ending December 31, 2023. The company was formerly known as Conversion Labs, Inc. and Immudyne, Inc. LifeMD, Inc. is incorporated in Delaware. The company's business address is 236 Fifth Avenue, Suite 400, New York, NY 10001.
Why It Matters
For investors and stakeholders tracking LifeMD, Inc., this filing contains several important signals. This filing provides shareholders with crucial information regarding corporate governance, executive compensation, and matters to be voted on at the upcoming shareholder meeting. As a DEF 14A filing, it is a standard disclosure for public companies and indicates the company is preparing for shareholder engagement and potential corporate actions.
Risk Assessment
Risk Level: low — LifeMD, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate disclosure rather than immediate financial or operational news.
Analyst Insight
Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand potential impacts on company strategy and shareholder value.
Key Numbers
- 2023-12-31 — Fiscal Year End (Period covered by the DEF 14A filing)
- 2024-04-29 — Filing Date (Date the DEF 14A was filed)
- 001-39785 — SEC File Number (SEC file number for LifeMD, Inc.)
Key Players & Entities
- LifeMD, Inc. (company) — Filer of the DEF 14A
- Conversion Labs, Inc. (company) — Former name of LifeMD, Inc.
- Immudyne, Inc. (company) — Former name of LifeMD, Inc.
- DE (jurisdiction) — State of incorporation for LifeMD, Inc.
- New York (location) — City of LifeMD, Inc.'s business and mail address
FAQ
When did LifeMD, Inc. file this DEF 14A?
LifeMD, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by LifeMD, Inc. (LFMDP).
Where can I read the original DEF 14A filing from LifeMD, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by LifeMD, Inc..
What are the key takeaways from LifeMD, Inc.'s DEF 14A?
LifeMD, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: LifeMD, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 29, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company was formerly known as Conversion Labs, Inc. and Immudyne, Inc..
Is LifeMD, Inc. a risky investment based on this filing?
Based on this DEF 14A, LifeMD, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating standard corporate disclosure rather than immediate financial or operational news.
What should investors do after reading LifeMD, Inc.'s DEF 14A?
Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand potential impacts on company strategy and shareholder value. The overall sentiment from this filing is neutral.
How does LifeMD, Inc. compare to its industry peers?
LifeMD, Inc. operates in the healthcare sector, specifically focusing on telehealth and direct-to-consumer medical services.
Are there regulatory concerns for LifeMD, Inc.?
As a publicly traded company, LifeMD, Inc. is subject to SEC regulations and disclosure requirements, including the filing of proxy statements.
Industry Context
LifeMD, Inc. operates in the healthcare sector, specifically focusing on telehealth and direct-to-consumer medical services.
Regulatory Implications
As a publicly traded company, LifeMD, Inc. is subject to SEC regulations and disclosure requirements, including the filing of proxy statements.
What Investors Should Do
- Review the executive compensation details to assess alignment with company performance.
- Examine any shareholder proposals and management's recommendations.
- Understand the agenda for the upcoming shareholder meeting.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a standard disclosure document for public companies and does not represent a change from previous filings in terms of its nature.
Filing Stats: 4,817 words · 19 min read · ~16 pages · Grade level 10.5 · Accepted 2024-04-29 16:59:31
Key Financial Figures
- $0.01 — 8,346 shares of common stock, par value $0.01 (the "Common Stock"), issued and outsta
Filing Documents
- formdef14a.htm (DEF 14A) — 791KB
- formdef14a_001.jpg (GRAPHIC) — 2KB
- formdef14a_002.jpg (GRAPHIC) — 3KB
- formdef14a_003.jpg (GRAPHIC) — 3KB
- formdef14a_004.jpg (GRAPHIC) — 46KB
- formdef14a_005.jpg (GRAPHIC) — 45KB
- image_001.jpg (GRAPHIC) — 190KB
- image_002.jpg (GRAPHIC) — 190KB
- 0001493152-24-017032.txt ( ) — 2610KB
- lfmd-20231231.xsd (EX-101.SCH) — 6KB
- lfmd-20231231_def.xml (EX-101.DEF) — 10KB
- lfmd-20231231_lab.xml (EX-101.LAB) — 63KB
- lfmd-20231231_pre.xml (EX-101.PRE) — 44KB
- formdef14a_htm.xml (XML) — 107KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 16 Summary Compensation Table 16 Named Executive Officer Employment Agreements 17 Outstanding Equity Awards at Fiscal Year End 19 Pay Versus Performance 20 DIRECTOR COMPENSATION 23
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 26 EQUITY COMPENSATION PLAN INFORMATION 28 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 29 AUDIT-RELATED MATTERS 31 Audit Committee Report 31 Audit Fees and Services 31 Pre-Approval Policies and Procedures 32 PROPOSAL 2: APPROVE THE THIRD AMENDED AND RESTATED 2020 PLAN 33 Proposal 3: Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers 40 Proposal 4: Ratification of the Selection of MARCUM LLP as LifeMD's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 41 OTHER MATTERS 42 Stockholder Proposals and Nominees 42 Annex A – LifeMD, Inc. Third Amended and Restated 2020 Equity and Incentive Plan A-1 LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, NY 10001 PROXY ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON FRIDAY, JUNE 14, 2024 This Proxy Statement is furnished in connection with the solicitation of Proxies by the Board of Directors (the "Board of Directors" or the "Board") of LifeMD, Inc. ("LifeMD," the "Company," "we" or "us") for use at the 2024 Annual Meeting of Stockholders (the "Annual Meeting") to be held on Friday, June 14, 2024, beginning at 12:00 p.m. Eastern Daylight Time, and at any adjournment or postponement thereof (the "Annual Meeting"), for the purposes set forth in the accompanying Notice of Annual Meeting of Stockholders. It is contemplated that this Proxy Statement and the accompanying form of proxy or voting instruction form (the "Proxy"), or a Notice of Internet Availability of Proxy Materials providing instructions on how to access these documents on the Internet and how to vote, will be mailed to the Company's stockholders of record as of the end of business on April 24, 2024 (the "Record Date"). The proxy materials will be first mailed on or about April 29, 2024. The Proxy enables you to appoint Justin Schreiber, our Chief Executive Off